VRTX 8-K 2026-10-20

VERTEX PHARMACEUTICALS INC / MA (VRTX) 8-K dated 2026-10-20 — accession 0000875320-26-000278. This URL is the filing, not the VRTX hub.

VERTEX PHARMACEUTICALS INC / MA (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..

VERTEX PHARMACEUTICALS INC / MA filed a 8-K on 2026-10-20. Accession 0000875320-26-000278.

Cached items: 5.02. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 30.0.

Not investment advice. The VRTX SEC hub lists recent forms. The stock page is the research view.